X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1617) 1617
Publication (168) 168
Book Review (6) 6
Magazine Article (5) 5
Conference Proceeding (2) 2
Book Chapter (1) 1
Dissertation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1407) 1407
pyrimidinones - therapeutic use (1148) 1148
male (698) 698
index medicus (681) 681
female (633) 633
lopinavir (609) 609
hiv infections - drug therapy (526) 526
adult (475) 475
pyrimidinones - pharmacology (434) 434
ritonavir - therapeutic use (399) 399
pyrimidinones - administration & dosage (388) 388
animals (369) 369
middle aged (364) 364
hiv protease inhibitors - therapeutic use (352) 352
treatment outcome (300) 300
pharmacology & pharmacy (295) 295
pyrimidinones - adverse effects (289) 289
infectious diseases (266) 266
drug therapy, combination (248) 248
anti-hiv agents - therapeutic use (245) 245
aged (209) 209
mice (182) 182
oncology (180) 180
viral load (180) 180
pyrimidinones - pharmacokinetics (175) 175
immunology (170) 170
mutation (167) 167
hiv infections - virology (164) 164
melanoma - drug therapy (163) 163
ritonavir - administration & dosage (156) 156
thymidine - analogs & derivatives (152) 152
antiviral agents - therapeutic use (151) 151
pyridones - therapeutic use (151) 151
nucleosides - therapeutic use (149) 149
hiv (147) 147
ritonavir (147) 147
drug therapy (146) 146
hiv-1 - drug effects (140) 140
therapy (135) 135
virology (133) 133
lamivudine - therapeutic use (132) 132
hepatitis b, chronic - drug therapy (131) 131
ritonavir - adverse effects (131) 131
cancer (127) 127
melanoma (127) 127
antineoplastic combined chemotherapy protocols - therapeutic use (126) 126
antineoplastic agents - therapeutic use (125) 125
pyrimidinones - chemistry (122) 122
hiv protease inhibitors - administration & dosage (120) 120
hiv protease inhibitors - adverse effects (119) 119
cd4 lymphocyte count (112) 112
protein kinase inhibitors - therapeutic use (110) 110
antiretroviral therapy, highly active (109) 109
proto-oncogene proteins b-raf - genetics (108) 108
research (108) 108
reverse transcriptase inhibitors - therapeutic use (107) 107
pyridones - administration & dosage (106) 106
sulfonamides - therapeutic use (106) 106
adolescent (102) 102
protease inhibitors (102) 102
rats (102) 102
cell line, tumor (100) 100
antiviral agents (99) 99
adenine - analogs & derivatives (96) 96
antiretroviral therapy (95) 95
microbiology (95) 95
care and treatment (94) 94
dose-response relationship, drug (94) 94
health aspects (93) 93
resistance (92) 92
skin neoplasms - drug therapy (92) 92
adenine - therapeutic use (88) 88
anti-hiv agents - administration & dosage (86) 86
article (86) 86
drug combinations (86) 86
drug resistance, viral (86) 86
hiv-1 (85) 85
lopinavir/ritonavir (85) 85
pharmacokinetics (85) 85
pyridines - therapeutic use (84) 84
imidazoles - administration & dosage (82) 82
oximes - administration & dosage (82) 82
tenofovir (81) 81
drug administration schedule (80) 80
organophosphonates - therapeutic use (80) 80
melanoma - genetics (79) 79
anti-hiv agents - adverse effects (78) 78
biochemistry & molecular biology (78) 78
proto-oncogene proteins b-raf - antagonists & inhibitors (78) 78
hiv-1 - genetics (77) 77
imidazoles - therapeutic use (77) 77
lamivudine (77) 77
rna, viral - blood (76) 76
analysis (75) 75
pyrimidinones - blood (75) 75
pyrimidinones - chemical synthesis (75) 75
trametinib (74) 74
retrospective studies (72) 72
drug interactions (71) 71
ritonavir - pharmacokinetics (70) 70
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1475) 1475
Spanish (36) 36
Japanese (29) 29
Chinese (24) 24
German (21) 21
French (14) 14
Russian (7) 7
Korean (5) 5
Italian (3) 3
Danish (2) 2
Hungarian (2) 2
Polish (2) 2
Portuguese (2) 2
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Mayo Clinic Proceedings, ISSN 0025-6196, 2011, Volume 86, Issue 10, pp. 1009 - 1026
Abstract Most viral diseases, with the exception of those caused by human immunodeficiency virus, are self-limited illnesses that do not require specific... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | HERPES-SIMPLEX-VIRUS | TENOFOVIR DISOPROXIL FUMARATE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | ORGAN TRANSPLANT RECIPIENTS | POSITIVE CHRONIC HEPATITIS | CHRONIC HEPATITIS-B | ALPHA-2A PLUS RIBAVIRIN | OF-THE-LITERATURE | RECURRENT GENITAL HERPES | HIV-INFECTED PATIENTS | Acyclovir - therapeutic use | Foscarnet - pharmacology | Hepatitis C - drug therapy | HIV Infections - epidemiology | Humans | Ganciclovir - analogs & derivatives | Interferons - therapeutic use | Oligopeptides - therapeutic use | Hepatitis - drug therapy | Adenine - therapeutic use | Lamivudine - therapeutic use | Ganciclovir - therapeutic use | Proline - pharmacology | Protease Inhibitors - therapeutic use | Guanine - therapeutic use | Oseltamivir - pharmacology | Virus Replication - drug effects | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Comorbidity | Interferons - pharmacology | Pyrimidinones - therapeutic use | Acyclovir - pharmacology | Zanamivir - therapeutic use | Herpesviridae Infections - drug therapy | Thymidine - analogs & derivatives | Valine - therapeutic use | Oligopeptides - pharmacology | Ribavirin - pharmacology | Guanine - analogs & derivatives | Oseltamivir - therapeutic use | Guanine - pharmacology | Hepatitis C - epidemiology | Nucleosides - pharmacology | Ganciclovir - pharmacology | Pyrimidinones - pharmacology | Influenza, Human - drug therapy | Drug Therapy, Combination | Nucleosides - therapeutic use | Acyclovir - analogs & derivatives | Ribavirin - therapeutic use | Valine - analogs & derivatives | Zanamivir - pharmacology | Adenine - pharmacology | Proline - therapeutic use | Organophosphonates - pharmacology | Hepatitis B, Chronic - drug therapy | HIV Infections - drug therapy | Lamivudine - pharmacology | Foscarnet - therapeutic use | Valine - pharmacology | Amantadine - pharmacology | Antiviral agents | Diagnosis | Research | Drug therapy | HIV infection | Health aspects | Symposium on Antimicrobial Therapy
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 08/2017, Volume 77, Issue 2, pp. 356 - 368
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 19, pp. 1813 - 1823
In patients with surgically resected melanoma, those with BRAF mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53%... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA-2B | PLACEBO | THERAPY | MEK INHIBITION | PHASE-III | DOUBLE-BLIND | HAZARD | IPILIMUMAB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Adjuvants, Immunologic - adverse effects | Young Adult | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Double-Blind Method | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasm Recurrence, Local | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Adolescent | Survival Analysis | Aged | Pyridones - therapeutic use | Melanoma - surgery | Mutation | Neoplasm Staging | Pyridones - adverse effects | Melanoma - mortality | Usage | Relapse | Patient outcomes | Analysis | Melanoma | Adjuvant treatment | Outcome and process assessment (Health Care) | Reports | Drug therapy | Cancer | Diseases | Medical imaging | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Survival | Skin cancer | Metastases | Medical prognosis | Immunotherapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 18, pp. 1694 - 1703
The combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with metastatic melanoma produced a significantly higher response... 
CELL LUNG-CANCER | METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL | EFFICACY | PATHWAY | SAFETY | KINASE | RESISTANCE | DOSE-ESCALATION TRIAL | RAF INHIBITORS | IMPROVED SURVIVAL | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Imidazoles - pharmacokinetics | Fever - chemically induced | Drug Therapy, Combination - adverse effects | Melanoma - genetics | Adult | Female | Imidazoles - therapeutic use | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | MAP Kinase Signaling System - drug effects | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyridones - therapeutic use | Mutation | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Melanoma | Product/Service Evaluations | Research | Antineoplastic agents | Antimitotic agents | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Drug therapy, Combination | Drug therapy | Cell survival | Protein kinase | Skin diseases | MAP kinase | Kinases | Patients | Drug dosages | Fever | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9534, pp. 476 - 482
Lopinavir-ritonavir is a preferred protease inhibitor co-formulation for initial HIV-1 treatment. Fosamprenavir-ritonavir has shown similar efficacy and safety... 
MEDICINE, GENERAL & INTERNAL | THERAPY | NAIVE PATIENTS | RECOMMENDATIONS | EFAVIRENZ | TENOFOVIR DF | RESISTANCE | AIDS | SOCIETY-USA PANEL | LOPINAVIR/RITONAVIR | NELFINAVIR | Dideoxynucleosides - administration & dosage | Organophosphates - administration & dosage | Lamivudine - administration & dosage | Ritonavir - administration & dosage | HIV-1 - drug effects | Humans | Lopinavir | Pyrimidinones - therapeutic use | Organophosphates - therapeutic use | Carbamates - administration & dosage | HIV Protease Inhibitors - administration & dosage | HIV-1 - genetics | Reverse Transcriptase Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Sulfonamides - therapeutic use | Lamivudine - therapeutic use | Ritonavir - therapeutic use | HIV Infections - drug therapy | Dideoxynucleosides - therapeutic use | Pyrimidinones - administration & dosage | Reverse Transcriptase Inhibitors - therapeutic use | Carbamates - therapeutic use | Drug Therapy, Combination | Sulfonamides - administration & dosage | Dosage and administration | Protease inhibitors | Comparative analysis | Drug therapy | HIV infection | Antiviral agents | Research | Drug therapy, Combination | Health aspects | Anti-HIV agents | Antiretroviral drugs | Human immunodeficiency virus--HIV | Samples | Clinical trials | Comparative studies | Clinical medicine | Disease control
Journal Article